6
Participants
Start Date
October 15, 2013
Primary Completion Date
December 10, 2014
Study Completion Date
April 9, 2018
Treatment with NY-ESO-1c259-modified T cells
"An intended total dose of ≥0.1-1e10 total cells will be administered as a single infusion. A low dose infusion of 1e8 to \< 1e9 will be allowed for patients if cells do not expand sufficiently to reach the target dose range.~For patients whose disease progresses and whose tumor still expresses tumor antigen and HLA-A201, a second infusion of up to 5e10 cells may be given."
Greenebaum Cancer Center, University of Maryland, Baltimore
City of Hope, Duarte
Lead Sponsor
Adaptimmune
INDUSTRY